|
Bayer CEO Marijn Dekkers calls for greater appreciation of innovation
|
20 November 2013 |
|
Bayer continues positive business momentum
|
03 November 2013 |
|
Bayer accelerates clinical development of promising new drug candidates
|
09 October 2013 |
|
Olivier Brandicourt appointed as new CEO of Bayer HealthCare
|
30 September 2013 |
|
Bayer's investigational drug Riociguat granted FDA orphan drug designation
|
26 September 2013 |
|
Bayer fights Chagas disease in Argentina together with Caritas
|
18 September 2013 |
|
Nexavar® (sorafenib) granted priority review for differentiated thyroid cancer in the U.S.
|
27 August 2013 |
|
Bayer: Life Sciences off to a good start in anniversary year
|
28 April 2013 |
|
Bayer to collaborate with the Children's Hospital & Research Center Oakland to fight rare blood diseases
|
07 March 2013 |
|
Bayer: continuing growth momentum
|
28 February 2013 |
|
Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of patients with gastrointestinal stromal tumors
|
25 February 2013 |
|
Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.
|
09 January 2013 |
|
Bayer's "Perspective on Innovation 2012"
|
15 November 2012 |
|
The largest clinical study of Bayer's Xarelto® (rivaroxaban)
|
13 November 2012 |
|
Bayer on track for a successful 2012
|
30 October 2012 |
|
Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer
|
30 September 2012 |
|
Bayer joins global initiative for better access to safe and effective contraception
|
26 September 2012 |
|
Bayer HealthCare starts special lab space-model CoLaborator™ for promising life science companies
|
11 September 2012 |
|
Bayer reports strong business performance in the second quarter of 2012
|
31 July 2012 |
|
FDA grants priority review to the new drug application for Bayer's Regorafenib
|
28 June 2012 |